Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Acro Biomedical CoROCO:6748 +16.57%66 Days Payable is 15.49 as of Dec. 2025, which is 41% above its 10-year median of 10.99. GuruFocus rates ROCO:6748 with a GF Score™ of 66/100 and a GF Value™ of NT$32.13 (Significantly Overvalued). The stock has 6 warning signs investors should review. Among 701 Biotechnology companies, Acro Biomedical Co ranks worse than 92.3% on this metric.
The historical rank and industry rank for Acro Biomedical Co's Days Payable or its related term are showing as below:
ROCO:6748'
s Days Payable Range Over the Past 10 Years
Min: 4.64 Med: 10.99 Max: 33.02
Current: 15.23
During the past 8 years, Acro Biomedical Co's highest Days Payable was 33.02. The lowest was 4.64. And the median was 10.99.
ROCO:6748's Days Payable is ranked worse than 92.3% of 701
companies
in the Biotechnology industry
Industry Median: 112.84
vs ROCO:6748: 15.23
Acro Biomedical Co's Days Payable
declined
from Dec. 2024 (17.55) to Dec. 2025 (15.49).
It may suggest that Acro Biomedical Coaccelerated paying its suppliers.
Acro Biomedical Co Days Payable Related Terms
Acro Biomedical Co Days Payable Historical Data
* Premium members only.
The historical data trend for Acro Biomedical Co's Days Payable can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
ROCO:6748 vs VRTX, REGN, ALNY: Days Payable Comparison
For the Biotechnology subindustry, Acro Biomedical Co's Days Payable, along with its competitors' market caps and Days Payable data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Acro Biomedical Co Days Payable vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Acro Biomedical Co's Days Payable distribution charts can be found below:
* The bar in red indicates where Acro Biomedical Co's Days Payable falls into.
Days Payable indicates the number of days that the account payable relative to cost of goods sold the company has. An increase of Days Payable may suggest that the company delays paying its suppliers.
Acro Biomedical Co's Days Payable for the fiscal year that ended in Dec. 2025 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Acro Biomedical Co (ROCO:6748) has a Days Payable of 15.49 as of Dec. 2025. Days payable represents the average amount of days a company waits to pay its invoices from suppliers. View historical data on Acro Biomedical Co and its competitors. This is 41% above median its historical median of 10.99. Over the past decade, Acro Biomedical Co's Days Payable has ranged from 4.64 to 33.02. According to the industry distribution chart, Acro Biomedical Co ranks #647 out of 701 companies in the Biotechnology industry, placing it in the top 92.3%.
Is Acro Biomedical Co's Days Payable too high?
Acro Biomedical Co's current Days Payable of 15.49 is 41% above median its 10-year median of 10.99. Over the past 10 years, this metric has ranged from a low of 4.64 to a high of 33.02. The Biotechnology industry median Days Payable is 112.84. Acro Biomedical Co's value of 15.49 is 86.3% below this industry median. Based on the distribution chart, Acro Biomedical Co ranks #647 out of 701 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, Acro Biomedical Co has a GF Score™ of 66/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Acro Biomedical Co's Days Payable compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Acro Biomedical Co ranks #647 out of 701 companies for Days Payable. This places Acro Biomedical Co in the lower half of its industry. The industry median Days Payable is 112.84. Acro Biomedical Co's value of 15.49 is 86.3% below this benchmark. Historically, Acro Biomedical Co's own Days Payable has ranged from 4.64 to 33.02 over the past decade. While the company's 10-year median is 10.99 vs. the industry median of 112.84, Acro Biomedical Co has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Days Payable for a Biotechnology company?
The median Days Payable among Biotechnology companies is 112.84, based on 701 companies in the industry. Companies in the top quartile (top 25%) have a Days Payable significantly above this median, while those in the bottom quartile fall well below. However, Days Payable should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Acro Biomedical Co's current Days Payable of 15.49 is 86.3% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Days Payable mean?
A high Days Payable can signal that a stock is expensive relative to its fundamentals. Days payable represents the average amount of days a company waits to pay its invoices from suppliers. View historical data on Acro Biomedical Co and its competitors. For the Biotechnology industry, the median Days Payable is 112.84 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Acro Biomedical Co's current Days Payable is 15.49, which is 41% above median its own 10-year median of 10.99. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Acro Biomedical Co stock overvalued right now?
Based on GuruFocus' analysis, Acro Biomedical Co (ROCO:6748) is currently considered Significantly Overvalued. The stock's GF Value™ is NT$32.13, compared to a current price of NT$295.50 — trading 819.7% above its estimated fair value. The current Days Payable is 15.49, which is 41% above median its 10-year median of 10.99 and 86.3% below the Biotechnology industry median of 112.84. Acro Biomedical Co's overall GF Score™ is 66/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Days Payable calculated?
Days Payable is calculated from a company's financial statements. For Acro Biomedical Co (ROCO:6748), the current Days Payable is 15.49 as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Acro Biomedical Co (ROCO:6748) Overvalued in 2026?
Based on GuruFocus' analysis, Acro Biomedical Co stock appears to be overvalued.
The current stock price of NT$295.50 is trading 819.7% above its estimated GF Value™ of NT$32.13.
GuruFocus considers Acro Biomedical Co to be Significantly Overvalued.
Key valuation signals for ROCO:6748:
Days Payable: 15.49 (41% above median its 10-year median of 10.99)
GF Value™: NT$32.13 vs. price of NT$295.50 (819.7% above fair value)
Industry Position: 86.3% below the Biotechnology median (#647 of 701)
No single metric tells the full story. See the ROCO:6748 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Acro Biomedical Co Ltd is a company whose technical team integrates the Research and development capabilities of Taiwan's major scientific research units and medical centers to jointly develop equipment for repairing organs and tissues in various parts of the human body. It mainly focuses on orthopedics, dentistry, cardiovascular specialists, ophthalmology, surgery, wound care, Medical equipment used in sports injuries and other specialties.
66GF Score
Get the complete analysis for ROCO:6748
Days Payable is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ROCO:6748 has been successfully added to your 
